Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL

HPV Clinical Trial

— VulVaccin  

Official title:

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL, a Randomised Placebo Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06052696
• Other study ID #: MEC-2023-0526
• Secondary ID: 2023-506792-94-0
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: December 1, 2023
• Est. completion date: December 1, 2030

Study information

• Verified date: September 2023
• Source: Erasmus Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Problem description:

Yearly, approximately 45000 women develop vulvar cancer worldwide. It is estimated that about 30% of all vulvar carcinomas are HPV related. As with other HPV related (pre)malignancies, the incidence has been rising over the past 20 years. The peak incidence of premalignant lesions of the vulva, also called Vulvar High Grade Squamous Intraepithelial Lesion (vHSIL), lies between 35 and 40 years of age. Multiple treatments are available, including surgery, laser vaporization, and topical imiquimod, with comparable success rate. Despite treatment, at least 30% of women will develop a recurrence within 2 years, with a much higher lifetime risk of recurrence. This results in multiple treatments with sometimes disfiguring effects and associated negative psychosocial and psychosexual impact. Woman with vulvar HSIL have a lifelong increased risk of vulvar cancer, and approximately 10% of women with (treated) vulvar HSIL will develop vulvar cancer within 10 years of first diagnosis. The risk of malignancy is significantly higher in women with recurrent disease, compared to women without recurrence.

Solution / research direction, To date, a successful strategy for reduction of recurrences of HSIL has not been established. The available positive evidence on the use of concurrent HPV vaccination in the treatment of vulvar HSIL is rising, yet insufficient to guide clinical practice. There is limited data that prophylactic HPV vaccination after treatment of vulvar HSIL reduces the chance of recurrence, therefore leading to a reduction in repeated (surgical) interventions. There are no randomised controlled studies supporting this data.

Aim The aim of current project is to determine the effectiveness of nonavalent HPV vaccination versus placebo in preventing recurrence in women treated for vulvar HSIL.

Plan of investigation This is a randomised, double blinded, placebo controlled trial in women treated for vulvar HSIL. Adult female patients, diagnosed with vulvar HSIL planned for treatment and no prior HPV vaccination will be included. Randomisation will be in a 1:1 ratio to additional nonavalent HPV vaccination versus additional placebo vaccination.

Expected outcome. Based on previous non-randomised studies, a significant reduction in recurrences, improvement of quality of life and a reduction of economic burden of the disease is expected.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: December 1, 2030
• Est. primary completion date: December 1, 2028
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 100 Years

Eligibility

Inclusion criteria

• Women 18 years or older

• Vulvar High-grade Squamous Intraepithelial Lesion (vHSIL), histologically proven

• Planned for treatment (surgical, laser or imiquimod) for vHSIL

Exclusion criteria

• Prior HPV vaccination

• (Micro-) invasive carcinoma or history of HPV related genital carcinoma (cervix, anal, vulva)

• Pregnancy

• Women allergic to vaccine components

• HIV infection

• Immune compromised patients (currently on immunosuppressive medication

Related Conditions & MeSH terms

• HPV
• Vulvar HSIL

Intervention

Drug:
• Gardasil 9 Suspension for Injection
After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
• Placebo
After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9% First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.

Locations

Country	Name	City	State
Netherlands	Erasmus MC	Rotterdam

Sponsors (2)

Lead Sponsor	Collaborator
Erasmus Medical Center	Dutch Cancer Society

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Does additional HPV vaccination reduce the recurrence of vHSIL compared to placebo?	Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months	24 months after last inclusion
Secondary	1. What is the effectiveness (complete remission) after treatment in vaccination versus placebo at 6 and 12 months?	1. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months	6 and 12 months after last inclusion
Secondary	2. What is the effectiveness (complete remission) after treatment in vaccination versus placebo at 6 and 12 months in primary episode vHSIL versus recurrence?	2. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between HPV vaccination and placebo at 6 and 12 months for primary vHSIL versus recurrent vHSIL.	6 and 12 months after last inclusion
Secondary	3. What is the effectiveness of adjuvant vaccination in different treatments of vHSIL (laser, imiquimod, excision) at 24 months?	3. Difference in number and percentage of patients with clinical recurrence rate of vulvar HSIL between the different treatment modalities	24 months after last inclusion
Secondary	4. How often is additional treatment for vHSIL needed in the study period? Is this different between the study groups?	4. Difference in number and percentage for additional treatment necessary after primary treatment.	24 months after last inclusion
Secondary	5. What is the effect of vaccination versus placebo on different HPV types (HPV type of primary and recurrence)?	5. Description and percentage of different HPV types. Percentage clearance of primary HPV type for vaccination versus placebo.	24 months after last inclusion
Secondary	6. What is the level of antibodies at baseline and after (placebo) vaccination?	6. Number of antibodies and percentage of increase or decrease after vaccination compared to antibodies before vaccination. Is there correlation between number or percentage of recurrence. Is that different in primary versus recurrent episode vHSIL	24 months after last inclusion
Secondary	7. Is the intervention cost effective?	7. incremental cost-effectiveness ratio (ICER), described the difference in costs and budget impact analysis	24 months after last inclusion
Secondary	8. Is Quality of life (measured with Euroqol 5D-5L questionnaire) improved after vaccination compared to placebo?	8.Description and change in numeric value and percentage in different score form questionnaires. Percentage increase of decrease QoL	24 months after last inclusion
Secondary	8. Is sexual health (measured with Female Sexual Function Index, FSFI questionnaire) improved after vaccination compared to placebo?	8.Description and change in numeric value and percentage in different score form questionnaires. Percentage increase of decrease sexual impact	24 months after last inclusion
Secondary	9. What is the effect of vaccination versus placebo on CIN/cervical cytology of the uterine cervix?	9. Difference number and percentage in HPV types cervical cytology and vHSIL before and after vaccination.	24 months after last inclusion
Secondary	10. Long-term follow-up: Is there a difference between vaccination and placebo group in number of recurrences of vHSIL (5 and 10 years) and the occurrence of vulvar malignancies (2, 5 and 10 years)?	10. Difference in number and percentage in recurrence rate of vulvar HSIL and vulvar cancer between HPV vaccination and placebo. Other HPV related disease known?	5 and 10 year